Actualidad de ROVI
As part of the Greenhouse Gas (GHG) Emissions Inventory, ROVI has decided to analyse the GHG emissions corresponding to the journeys made by each of the company’s employees from their place of residence to their workplace in 2020 and 2021.
Help us to analyse ROVI’s impact on the environment in greater depth by completing the internal mobility survey.
IMPORTANT: fill in ONLY those workers who do NOT have a company car.
Take the survey HERE
You have until 8 April
For years, ROVI has been cooperating and collaborating with different associations in the inclusion of people with other abilities in the workplace. Thanks to its work with the Prodis Foundation and Down Granada, ROVI has participated in three projects to accompany people with intellectual disabilities in their process of adapting to their work at the Granada, Pozuelo and Madrid offices.
This adaptation process consists of three main phases:
Javier Angulo, Director of Human Resources at ROVI, explains: “This accompaniment model provides us with a great deal of security for the companies, as it facilitates the transition to the real world of work for the candidates, and for the work teams it allows us to better understand the needs they may have for their adaptation. These young people show that, with the right training, they are perfectly qualified for employment. In this sense, at ROVI we continue to be committed to facilitating the integration of people with intellectual disabilities into the workplace, as we understand that this is an essential step for the development and autonomy of any person”.
“Thanks to our qualified team of labour mediators and professionals, the Prodis Foundation is able to make the Labour Inclusion Service programme a reality, thus supporting people with intellectual disabilities entering the labour market. This collaboration between the foundation and companies has been vital not only to help in accessing a job, but also to improve their quality of life and their real participation in society,” said María Gil, Director of Communication at the Prodis Foundation.
Laboratorios Farmacéuticos Rovi, S.A. was certified carbon neutral in 2021 for the second year running. Attaining this important milestone was the result of the Group’s Environmental and Social Sustainability Policy and the effort made to reduce the environmental impact of all its activities, within the framework of its “Avoid, reduce, compensate” strategy
Juan López-Belmonte, ROVI’s Chairman and Chief Executive Officer, said: “Our company has significant industrial activity, which makes us especially sensitive to the impact we have on the environment. For this reason, we apply a policy to control and optimise consumption of natural resources at all our plants and make important investments to optimise our efforts to avoid, reduce and offset our emissions”.
ROVI has four medicine production plants in Spain and, for many years, has been applying policies to mitigate the environmental impact of its facilities. Thus, as a company committed to a rational use of energy, ROVI has a specific line of work addressing the optimisation of energy consumption in the course of its activities. Specifically, the actions taken focus on:
For a long time, ROVI been defending and applying its commitment to economic business growth that respects the environment, in line with the United Nations Sustainable Development Goals, more specifically, Goal 12 of the Agenda 2030 “Responsible production and consumption”.
Following the evolution of the incidence of the pandemic in Spain and the gradual reduction of COVID-19 infections, ROVI will recover face-to-face assistance for employees in NON-industrial offices as of 7 March.
All these measures will be reviewed according to the evolution of the indications of the health authorities applying to the workplaces and the evolution of the epidemiological situation.
We would like to remind you that, as of 7 March, any ROVI employee who:
Moderna and Laboratorios Farmacéuticos Rovi today announced a long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of ROVI’s facilities located in Madrid, San Sebastián de los Reyes and Alcalá de Henares.
This new agreement, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity to increase across ROVI’s facilities in Madrid, Spain. In addition to producing Moderna’s COVID-19 vaccine, ROVI’s platform could also be utilized to service future Moderna mRNA vaccine candidates.
“ROVI has been a pivotal partner in supporting the manufacturing of our COVID-19 mRNA vaccine for countries outside of the U.S., and this long-term agreement expands our partnership and allows for further scale-up for future mRNA medicines,” said Juan Andrés, Moderna’s Chief Technical Operations and Quality Officer.
Mr. Juan López-Belmonte Encina, ROVI’s Chairman and Chief Executive Officer, said: “We are delighted to expand our collaboration with Moderna and become a long-term manufacturing partner. At ROVI we are working to contribute all our experience as a high-technological-value contract manufacturer of injectables to the solution of this pandemic and we are confident of our ability to take part in the manufacturing of new mRNA candidates in the future.”
Moderna and ROVI are expected to finalize details of this agreement in the first quarter of 2022.
Today, ROVI has announced that the European Commission has authorised the marketing of Okedi® (Risperidone ISM®) for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, since, as of the first injection, it provides immediate and sustained plasmatic drug levels and does not require loading doses or supplementation with oral risperidone.
This approval is based on the positive results of the pivotal PRISMA-3 study on the efficacy and safety of Risperidone ISM® in schizophrenia patients.
“We are very excited about the European Commission’s approval of Risperidone ISM® because we think our medicine will be able to contribute to the clinical management of schizophrenia patients. Likewise, we hope to launch the product in Europe in the second quarter of 2022”, commented Juan López-Belmonte Encina, ROVI’s Chairman and Chief Executive Officer.
Regarding other territories, ROVI filed the application for marketing authorisation of Risperidone ISM® with the United State Health authorities, the U.S. Food and Drug Administration (“FDA”) on 24 November, 2020 and the dossier is currently being reviewed by the FDA. Recently, the FDA informed ROVI of a delay in making a decision on the grant of said marketing authorisation.
Last week we launched a simulated phishing attack, with the subject line: “Urgent – Your email account is full”. The objective was to measure the level of awareness and reaction we have in the organisation to this type of attack.
This exercise has shown that, although many of you have applied what you learnt in the cybersecurity campaigns conducted in 2021, others did not identify the danger signs and fell for the scam, allowing your credentials, username and password to be stolen; this is very serious for the security of our company.
During this year 2022 we will continue with a new campaign to reinforce and raise awareness of everything related to cybersecurity. Those of you who have fallen into the deception of this simulation will receive a special mandatory training action that will be communicated to you individually.
We would like to take this opportunity to congratulate those who have applied what they have learned and remind you of the keys to phishing, the most important of which is to know what can be asked of you and in what way, to be surprised by what is not normal and to ask if you have any doubts.
Click on the following image to sign up
ROVI and Moderna received a visit from Pedro Sánchez this weekend at the ROVI manufacturing plant in Granada, to see the start-up of a new production line for the active ingredient of the mRNA vaccine at this facility.
The President of the Government, together with the Minister of Health, Consumer Affairs and Social Welfare, Carolina Darias, and the Mayor of the city, Francisco Cuenca, were able to tour the facilities accompanied by Juan López-Belmonte, President and CEO of ROVI; Miguel Ángel Ortega, Industrial Director of ROVI; and Juan Carlos Gil, Managing Director of Moderna.
For the first time, a Spanish facility has the potential to not only fill the vials, but to run the entire production of a messenger RNA vaccine, which puts the country in a “key” position in the fight against the pandemic, President Sánchez stressed.
We indicate the amounts of allowances and mileage that apply from 1 January 2022: